Women’s cardiovascular health is an urgent clinical unmet need as reported by the European Society of Cardiology (ESC), as cardiovascular disease (CVD) risk in women still tends to be underestimated by clinicians and women themselves. CVD is under-diagnosed, under-treated and poorly understood, more so in women in the 40-60 age group, when personalised risk assessment and prevention can have a positive impact on their health. In this context, CARAMEL will deliver an innovative personalised prevention model aimed at women 40-60yrs based upon a risk assessment stratification model considering sex and gender specific risk factors and a self-assessment and self-management approach using innovative digital technologies, empowering women to optimise their cardiovascular health. The proposed CVD-Risk Assessment and Stratification scheme will only be possible by the cumulative risk factors analysis, fueled by AI, emerging from a wide number of different data sources, including clinical data from EHR, medical imaging, biomarkers, metabolomics, lifestyle information (sleep, physical activity, diet) from large cohorts and biobanks. A consortium composed by 25 partners and Affiliated Entities coming from 11 countries, composed by 9 clinical entities, 6 research organisations and 10 industry and SMEs will develop, test and validate the personalised prevention program in observational and interventional studies in clinical sites in Colombia, Croatia, Greece, Lithuania and Spain. To that end, engagement of women aged 40-60, will take place from the onset on the co-design and co-creation of the studies and the self-management app ecosystem to be developed. Likewise, Gender in research will be mainstreamed all along the intervention. CARAMEL will also deliver policy recommendation and clinical guidelines supporting the design and update of CVD Plans by health authorities and healthcare providers, considering novel AI based risk models, applicable to women aged 40-60 yrs.

Multi-cloud applications refer to applications that dynamically can distribute their components over heterogeneous cloud resources and still hold the functional, business and non-functional properties (NFP) declared in their SLAs. The main objective of the DECIDE action is to provide a new generation of multi-cloud service-based software framework, enabling techniques and mechanisms to design, develop, and dynamically deploy multi-cloud aware applications in an ecosystem of reliable, interoperable, and legal compliant cloud services (DECIDE DevOps Framework). DECIDE will provide a set of architectural patterns and the needed tools (DECIDE ARCHITECT) to develop and operate (following the DevOps approach) multi-cloud aware applications that can be dynamically self-adapted to be re-deployed using the best combination of cloud services. DECIDE will also set up an ecosystem of trusted, interoperable and legally compliant cloud services (ACSmI-Advance Cloud Service meta-Intermediator) and the required mechanisms to register, discover, compose, use and assess them. One of the key innovations of the DECIDE solution relies on the development of the OPTIMUS deployment simulation tool capable of evaluating and optimizing the resulting non-functional characteristics from the user’s perspective considering a set of given cloud resources alternatives. The OPTIMUS deployment simulation tool, together with the continuous deployment supporting tool (DECIDE ADAPT), will provide the most adequate deployment application topology based on a set of users’ requirements automating the provisioning and selection of deployment scripts for multi-cloud applications. Three use cases will be conducted to validate. DECIDE will innovate by tackling with multi-cloud and non-functional aspects and moreover by incorporating a DevOps approach to the whole solution DECIDE outcomes, covering the specific needs of different multi-cloud applications for on-line gaming, e-Health and Network management.

The overall objective of TrustChain is to create a portfolio of Next Generation Internet protocols and an ecosystem of decentralised software solutions that reach the highest standards of humanity such as those chartered by the United Nations including the respect of human rights, ethics, sustainability, energy efficiency, our care for the environment and our respect for the World’s cultural history. TrustChain will tackle several challenges pertaining to trustworthy and reliable digital identity, to resilient, secure and reliable data pathways, to economics and trading of data, to energy efficiency for data storage, transport and sharing, to seamless services and data flows. A new trustworthy data governance and sharing model in line with the European regulatory framework and taking into account European values will be developed that will ensure Trusted Data Ecosystems. Third party top Internet innovators will be selected through 5 open calls focus on topics of the (1) Decentralised digital identity, (2) the User privacy and data governance, (3) Economics and democracy, (4) Multi chains support for NGI protocols, and (5) Green scalable and sustainable DLTs, which is an essential need of the day. TrustChain addresses the second research area of the Human 01-03 call in particular to tackle the current limitations of decentralised technologies, such as Blockchain and DLT, including those related to scalability, interoperability, energy efficiency, privacy or security, in order to make them dependable building blocks of the future Internet. TrustChain will explore DLT-based solutions, enabling the exploitation of data coming from a high number and various types of sources, eliminating data silos through decentralised and interoperable approaches, while helping individuals and organisations better govern their data when they participate in joint value chains where cooperating partners can also be competitors.

AI4Lungs will develop and validate novel AI-based tools and computational models to improve patient stratification optimising diagnosis and treatment of infectious and non-infectious respiratory diseases. Diagnosis of respiratory disease comprises a complex assessment of several multiple exams over time that together characterise the patient condition. Streamlined into existing clinical pathways, AI4Lungs will support clinicians and other stakeholders in decision making along the patient journey from initial suspicion to diagnosis, and treatment planning. The models incorporate clinical partners’ multiple data sources, registries and open national/international databases, including multiple data types from medical records, imaging data as well as novel data from digital stethoscope and –omics. AI4Lungs stratification strategy will build computational models employing structured and unstructured data modalities, leading to more accurate positioning of patients and enabling them to benefit from global data and knowledge shared during all stages of care, focusing on diagnosis and treatment planning. With scale up, AI4Lungs will support any patient from any country, any hospital no matter how remote or small, by stratifying them among all of Europe’s patients from that cluster, gaining access to the collective expertise, experience and information on optimal care options. In parallel, health systems will reduce costs and effort in unnecessary testing, ineffective treatments and emergency services, optimizing use of health technologies and resources. AI4Lungs patient stratification tools will focus on respiratory diseases, a complex and broad set of disorders with high disease burden. AI and real world data combined with innovative holistic diseases modelling, will offer a solution for allocating resources more efficiently, making best treatment pipelines accessible to more patients while complying with FAIR principles and relevant regulatory and ethical guidelines.

With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.